Bay­er gets its hands on Acuitas' LNP as it lines up first shots at gene edit­ing

Bay­er has signed up to be the lat­est part­ner with Acuitas Ther­a­peu­tics, work­ing with a spe­cial­ist provider whose lipid nanopar­ti­cles were used to de­liv­er mul­ti­ple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER